X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8991) 8991
Publication (566) 566
Book Chapter (152) 152
Dissertation (122) 122
Conference Proceeding (92) 92
Book Review (87) 87
Book / eBook (9) 9
Web Resource (6) 6
Data Set (5) 5
Magazine Article (3) 3
Government Document (2) 2
Paper (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4448) 4448
drug interactions (3424) 3424
pharmacology & pharmacy (3290) 3290
drug-drug interactions (2901) 2901
index medicus (2792) 2792
animals (2321) 2321
drug-drug interaction (2167) 2167
male (2167) 2167
pharmacokinetics (1541) 1541
female (1449) 1449
adult (974) 974
rats (923) 923
middle aged (862) 862
metabolism (820) 820
in-vitro (707) 707
receptors, drug - drug effects (670) 670
aged (634) 634
analysis (564) 564
drug–drug interaction (563) 563
pharmacology (559) 559
inhibition (537) 537
dose-response relationship, drug (536) 536
drugs (501) 501
mice (486) 486
toxicology (484) 484
drug–drug interactions (474) 474
p-glycoprotein (473) 473
kinetics (429) 429
cytochrome p450 (427) 427
drug interaction (406) 406
cytochrome p-450 enzyme system - metabolism (401) 401
cytochrome p-450 (397) 397
biochemistry & molecular biology (387) 387
young adult (380) 380
area under curve (375) 375
drug therapy, combination (361) 361
in vitro techniques (357) 357
pharmacology/toxicology (340) 340
research (339) 339
models, biological (335) 335
chemistry, multidisciplinary (326) 326
enzymes (317) 317
liver (316) 316
human liver-microsomes (310) 310
drug therapy (304) 304
adolescent (294) 294
prediction (290) 290
administration, oral (273) 273
rats, sprague-dawley (267) 267
therapy (265) 265
pharmacy (264) 264
cytochrome p-450 cyp3a - metabolism (260) 260
metabolites (259) 259
polypharmacy (255) 255
cross-over studies (249) 249
liver - metabolism (248) 248
cancer (246) 246
chemistry, medicinal (245) 245
cyp3a4 (245) 245
pharmaceutical preparations - metabolism (243) 243
time factors (243) 243
complications and side effects (240) 240
microsomes, liver - metabolism (240) 240
cells, cultured (237) 237
physiological aspects (237) 237
pharmacodynamics (232) 232
medicine & public health (229) 229
drug design (225) 225
oncology (222) 222
aged, 80 and over (221) 221
safety (219) 219
biomedicine (216) 216
protein binding (212) 212
article (210) 210
microsomes, liver - drug effects (210) 210
microsomes, liver - enzymology (210) 210
risk factors (210) 210
internal medicine (209) 209
enzyme inhibitors - pharmacology (207) 207
expression (204) 204
drug metabolism (202) 202
induction (200) 200
warfarin (193) 193
drug synergism (189) 189
dosage and administration (186) 186
risk (184) 184
care and treatment (180) 180
healthy-volunteers (180) 180
hiv (175) 175
binding sites (174) 174
absorption (172) 172
health aspects (172) 172
ketoconazole (171) 171
medicine (170) 170
cytochrome p-450 enzyme inhibitors (168) 168
hiv infections - drug therapy (168) 168
prevalence (168) 168
toxicity (168) 168
liver - drug effects (167) 167
hepatocytes - metabolism (166) 166
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5891) 5891
Japanese (1797) 1797
Chinese (1429) 1429
German (63) 63
French (42) 42
Spanish (32) 32
Russian (27) 27
Slovenian (10) 10
Czech (7) 7
Korean (6) 6
Portuguese (6) 6
Polish (5) 5
Italian (4) 4
Turkish (3) 3
Hungarian (2) 2
Bulgarian (1) 1
Dutch (1) 1
Norwegian (1) 1
Slovak (1) 1
Thai (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacokinetics, ISSN 0312-5963, 1/2011, Volume 50, Issue 1, pp. 25 - 39
Etravirine (formerly TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against wild-type and NNRTI-resistant strains of HIV-1.... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Drug-interactions | Ribavirin, drug interactions | Antiepileptic-drugs, drug interactions | Simvastatin, drug interactions | Voriconazole, drug interactions | Dexamethasone, drug interactions | Fibric-acid-derivatives, drug interactions | Rifampicin, drug interactions | Opioid-analgesics, drug interactions | Antidepressants, drug interactions | Atorvastatin, drug interactions | Antiretrovirals, drug interactions | Anti-infectives, drug interactions | Histamine-H2-receptor-antagonists, drug interactions | Diazepam, drug interactions | Ketoconazole, drug interactions | Fluconazole, drug interactions | Hypericum, drug interactions | HMG-CoA-reductase-inhibitors, drug interactions | Oral-contraceptives, drug interactions | Sildenafil, drug interactions | Omeprazole, drug interactions | Buprenorphine, drug interactions | Rosuvastatin, drug interactions | Non-nucleoside-reverse-transcriptase-inhibitors, drug interactions | Type-5-cyclic-nucleotide- phosphodiesterase-inhibitors, drug interactions | Corticosteroids, drug interactions | Paroxetine, drug interactions | Fluoxetine, drug interactions | Rifapentine, drug interactions | Ethinylestradiolnorethisterone, drug interactions | Ranitidine, drug interactions | Etravirine, drug interactions | Antifungals, drug interactions | Digoxin, drug interactions | Warfarin, drug interactions | Methadone, drug interactions | Fluvastatin, drug interactions | Rifabutin, drug interactions | Sertraline, drug interactions | Azithromycin, drug interactions | Pharmacokinetics | Calcineurin-inhibitors, drug interactions | Itraconazole, drug interactions | Proton-pump-inhibitors, drug interactions | Clarithromycin, drug interactions | TRANSCRIPTASE INHIBITOR ETRAVIRINE | METABOLISM | EXPERIENCED HIV-1-INFECTED PATIENTS | TMC125 ETRAVIRINE | HIV-NEGATIVE VOLUNTEERS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | HUMAN LIVER | PLACEBO-CONTROLLED TRIAL | 2 DIFFERENT FORMULATIONS | CLINICAL PHARMACOKINETICS | Reverse Transcriptase Inhibitors - adverse effects | Reverse Transcriptase Inhibitors - pharmacokinetics | Drug Interactions | Drug-Related Side Effects and Adverse Reactions | Humans | Pyridazines - pharmacokinetics | Drug Therapy, Combination | Pyridazines - adverse effects | Etravirine | Drug interactions | Physiological aspects | Dosage and administration | Research | Properties | Drug therapy | HIV infection
Journal Article
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 5/2008, Volume 25, Issue 5, pp. 1063 - 1074
To assess the consequences of multiple inhibitors and differential inhibition mechanisms on the prediction of 12 gemfibrozil drug–drug interactions (DDIs). In... 
Biomedical Engineering | Biochemistry, general | CYP2C8 | Biomedicine | enzyme inhibition | Pharmacy | drug–drug interactions | Medical Law | Pharmacology/Toxicology | gemfibrozil | OATP1B1 | Enzyme inhibition | Drug-drug interactions | Gemfibrozil | PARALLEL PATHWAYS | CYP3A4 IN-VITRO | HUMAN LIVER-MICROSOMES | TRANSPLANT RECIPIENTS | HEPATIC-UPTAKE | CHEMISTRY, MULTIDISCIPLINARY | ATORVASTATIN | drug-drug interactions | PHARMACOKINETICS | PLASMA-CONCENTRATIONS | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | CYCLOSPORINE | Cell Line | Cytochrome P-450 CYP2C8 | Hypolipidemic Agents - adverse effects | Predictive Value of Tests | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Area Under Curve | Humans | Immunosuppressive Agents - pharmacokinetics | Enzyme Inhibitors - pharmacology | Gemfibrozil - pharmacokinetics | Gemfibrozil - adverse effects | Aryl Hydrocarbon Hydroxylases - metabolism | Carrier Proteins - metabolism | Drug Interactions | Glucuronides - metabolism | Cyclosporine - adverse effects | Cyclosporine - pharmacokinetics | Immunosuppressive Agents - adverse effects | Kinetics | Hypolipidemic Agents - pharmacokinetics | Databases, Factual | Physiological aspects | Complications and side effects | Analysis | Drug interactions | Low density lipoproteins | Enzymes | Biomedical research | Inhibitor drugs | Predictions | Pharmacology | Models | Metabolism
Journal Article
Journal Article
Journal Article
Pharmacology and Therapeutics, ISSN 0163-7258, 04/2019, Volume 196, pp. 204 - 215
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 05/2018, Volume 115, Issue 18, pp. E4304 - E4311
Journal Article
01/2014
Many people have the mistaken notion that, being natural, all herbs and foods are safe; this is not so. Very often, herbs and food may interact with... 
drug–drug interaction | Cytochrome P-450 | Herbal Preparation | herbal–drug interaction | Herbal drug
Web Resource
Journal of Gastroenterology and Hepatology, ISSN 0815-9319, 05/2018, Volume 33, Issue 5, pp. 1100 - 1107
Background & AimsDrug-drug interactions (DDIs) with ombitasvir/paritaprevir/ritonavir with or without dasabuvir and with or without ribavirin (OBV/PTV/rDSVRBV)... 
Paritaprevir | Ombitasvir | Hepatitis C virus | Ritonavir | Dasabuvir | Drug–drug interactions | ANTIVIRAL AGENTS | ABT-450/R-OMBITASVIR | INCREASES | REGIMEN | RISK | C VIRUS-INFECTION | Drug-drug interactions | HCV | GASTROENTEROLOGY & HEPATOLOGY | HEPATITIS-C | Complications and side effects | Hepatitis C | Drug interactions | Ribavirin | Antiviral agents | Clinical trials | Interferon | Clinical medicine | Patients
Journal Article